DO NEW CANCER DRUGS OFFER GOOD VALUE FOR MONEY? THE PERSPECTIVE OF ONCOLOGISTS, PAYERS, PATIENTS, AND GENERAL POPULATION

DO NEW CANCER DRUGS OFFER GOOD VALUE FOR MONEY? THE PERSPECTIVE OF ONCOLOGISTS, PAYERS, PATIENTS, AND GENERAL POPULATION